Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 7/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | CPT1A | P50416 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936017 | 0.78 | NR1H2 (0.38) | SCD5SCDGRM5SRCNPC1 | |
| SCHEMBL27564986 | 0.75 | RIPK1 (0.62) | RIPK1SCD5SCDHSP90AA1 | |
| SCHEMBL28171621 | 0.72 | RIPK1 (0.67) | RIPK1SCD5SCDHSP90AA1 | |
| SCHEMBL1576663 | 0.68 | RIPK1 (0.73) | RIPK1SCD5SCDHSP90AA1 | |
| SCHEMBL4046232 | 0.67 | RIPK1 (0.51) | RIPK1HPGD | |
| SCHEMBL4046089 | 0.66 | RIPK1 (0.50) | RIPK1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL33532001 | 0.65 | RIPK1 (0.58) | RIPK1SCD5SCDHSP90AA1 | |
| SCHEMBL30878611 | 0.65 | RIPK1 (0.55) | RIPK1SCD5HSP90AA1 | |
| SCHEMBL23064471 | 0.64 | PPID (0.48) | RIPK1SCD5HSP90AA1 | |
| SCHEMBL28537451 | 0.64 | PPID (0.48) | RIPK1SCD5HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665719-B1 | FUSED DIHYDROFURANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| EP-2651931-B1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8778926-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8669271-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-11 | — | — | US | disclosed |
| EP-2665719-A1 | FUSED DIHYDROFURANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2013-11-27 | — | — | EP | disclosed |
| EP-2651931-A1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130018030-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-17 | — | — | US | disclosed |
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012080476-A1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | GPR119, GPR3, MRGPRX2 | RIPK1 4674/4885SCD5 1940/4885SCD 2078/4885 |
| US-20130018030-A1 | New compounds, pharmaceutical compositions and uses thereof | GPR119, GPR3, MRGPRX2 | RIPK1 4619/4885SCD5 2395/4885SCD 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.